Asset profile
Agalsidase beta · Fabrazyme
Protein / enzyme therapeutic
Evidence outlook
Approved: Fabry Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
3 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 2 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Agalsidase Beta (Fabrazyme): this drug | Approved | Protein / enzyme therapeutic | Alpha-galactosidase A (GLA / α-Gal A) | ||
| Migalastat (Galafold) | Approved | Small molecule | Alpha-galactosidase A (GLA / α-Gal A) | ||
| Pegunigalsidase Alfa | Approved | Protein / enzyme therapeutic | — | ||
| Isaralgagene Civaparvovec | Not yet studied | Gene therapy / editing | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.